News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade/hiranandanihospital.org
Apr 16, 2025, 17:55

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:

“LET’S PLAY DEVIL’S ADVOCATE:

Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –

Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.

I broke it down—with counterarguments .

Do Check this out.”

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor

Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo 

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

More posts featuring Amol Akhade.

Amol Akhade Breast Cancer cancer cancer treatment Ian F. Tannock OncoDaily Oncology Qamar J. Khan Tito Fojo
Special Coverage
Blog
May 29, 2025, 15:41
Meet The Translational and Therapeutic Research in Pancreatic Cancer Team at Cancer Research Centre of Marseille - AFRCP
Career
May 29, 2025, 15:32
Join University of Arizona Cancer Center at ASCO 2025 to Explore Oncology Job Opportunities
Blog
May 29, 2025, 15:10
FORwards Special Interest Group Webinar on Fear of Cancer Recurrence Featuring Expert Christine Maheu
Blog
May 29, 2025, 14:19
Anna Cabanes on ATOM Coalition's Milestone in Global Cancer Access Program at the Recent Workshop in Zambia
Insight
May 29, 2025, 14:15
New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer
Opinion
May 29, 2025, 13:47
Robin Zon and Andy Guinigundo Highlighted the Importance of Team Attendance at ASCO 2025
Blog
May 29, 2025, 13:35
Habib Nehmé Highlights Elekta’s Record Fourth Quarter and Global Teamwork
Opinion
May 29, 2025, 13:32
List of 10 ADC Presentations Not to Miss at the ASCO 2025 Curated by Paolo Tarantino and Raffaele Colombo
Blog
May 29, 2025, 13:16
Dana Bryson Highlights ACT for Children's Progress in Expanding Pediatric Cancer Access
Insight
May 29, 2025, 13:11
START and OneOncology Partner to Expand Access to Early-Phase Oncology Trials
Blog
May 29, 2025, 13:01
Ruben Mesa: Wonderful panel at CancerX by members of our Advocate Health Cancer National Service Line
Blog
May 29, 2025, 12:53
Aleix Prat: Representing Both the Clínic Barcelona Comprehensive Cancer Center and Reveal Genomics at ASCO25